NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company ...

Since it has a market capitalisation of US$393m, Y-mAbs Therapeutics' US$22m in cash burn equates to about 5.6% of its market value. That's a low proportion, so we figure the company would be able to ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Justin Walsh has given his Buy rating due to a combination of factors concerning Y-Mabs Therapeutics’ recent ...

Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the previous year, the company earned ($0.18) earnings per share.

Check the time stamp on this data. Updated AI-Generated Signals for Y-mabs Therapeutics Inc. (YMAB) available here: YMAB.

Check the time stamp on this data. Updated AI-Generated Signals for Y-mabs Therapeutics Inc. (YMAB) available here: YMAB.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a market capitalization of $442.5 million, is navigating a critical juncture in its development of novel ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a market capitalization of $442.5 million, is navigating a critical juncture in its... ByInvesting.com ...

Investing.com - Y mAbs Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Y mAbs Therapeutics announced ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...